Numerous studies have been published on the health effects of yogurt and the bacterial cultures used in the production of yogurt. The benefits of yogurt and LAB on gastrointestinal health have been investigated in animal models and, occasionally, in human subjects. Further well-designed, controlled human studies of adequate duration are needed to confirm or extend these findings.
Numerous studies have been published on the health effects of yogurt and the bacterial cultures used in the production of yogurt. The benefits of yogurt and LAB on gastrointestinal health have been investigated in animal models and, occasionally, in human subjects. Further well-designed, controlled human studies of adequate duration are needed to confirm or extend these findings.
Numerous studies have been published on the health effects of yogurt and the bacterial cultures used in the production of yogurt. The benefits of yogurt and LAB on gastrointestinal health have been investigated in animal models and, occasionally, in human subjects. Further well-designed, controlled human studies of adequate duration are needed to confirm or extend these findings.
1,2 Oskar Adolfsson, Simin Nikbin Meydani, and Robert M Russell ABSTRACT In recent years, numerous studies have been published on the health effects of yogurt and the bacterial cultures used in the production of yogurt. In the United States, these lactic acidproducing bacteria (LAB) include Lactobacillus and Streptococcus species. The bene- fits of yogurt and LAB on gastrointestinal health have been inves- tigated in animal models and, occasionally, in human subjects. Some studies using yogurt, individual LABspecies, or both showed prom- ising health benefits for certain gastrointestinal conditions, includ- ing lactose intolerance, constipation, diarrheal diseases, colon can- cer, inflammatory bowel disease, Helicobacter pylori infection, and allergies. Patients withanyof these conditions couldpossiblybenefit fromthe consumptionof yogurt. The benefits of yogurt consumption to gastrointestinal function are most likely due to effects mediated through the gut microflora, bowel transit, and enhancement of gas- trointestinal innate and adaptive immune responses. Although sub- stantial evidence currently exists to support a beneficial effect of yogurt consumptionongastrointestinal health, there is inconsistency in reported results, which may be due to differences in the strains of LAB used, in routes of administration, or in investigational proce- dures or to the lack of objective definition of gut health. Further well-designed, controlled human studies of adequate duration are needed to confirm or extend these findings. Am J Clin Nutr 2004;80:24556. KEY WORDS Yogurt, gut function, gut immunity, gastroin- testinal diseases, gut microflora INTRODUCTION Components of the human intestinal microflora and of the foodenteringthe intestine mayhave harmful or beneficial effects on human health. Abundant evidence implies that specific bac- terial species used for the fermentation of dairy products such as yogurt and selected from the healthy gut microflora have pow- erful antipathogenic and antiinflammatory properties. These mi- croorganisms are therefore involved with enhanced resistance to colonizationof pathogenic bacteria inthe intestine, whichhas led to the introduction of novel modes of therapeutic and prophy- lactic interventions based on the consumption of monocultures and mixed cultures of beneficial live microorganisms as probi- otics. Probiotics are defined as living microorganisms, which on ingestion in sufficient numbers, exert health benefits beyond inherent basic nutrition (1). Yogurt is one of the best-known of the foods that contain probiotics. Yogurt is defined by the Codex Alimentarius of 1992 as a coagulated milk product that results fromthe fermentation of lactic acid in milk by Lactobacillus bulgaricus and Streptococ- cus thermophilus (2). Other lactic acid bacteria (LAB) species are now frequently used to give the final product unique charac- teristics. As starter cultures for yogurt production, LAB species display symbiotic relations during their growth in milk medium (3). Thus, a carefully selected mixture of LAB species is used to complement each other and to achieve a remarkable efficiency in acid production. Furthermore, to increase the number of LAB that survive the low pH and high acidity of the gastrointestinal environment, some LAB species that are indigenous to the hu- man intestine have been used in yogurt production. To meet the National Yogurt Associations criteria for live and active cul- ture yogurt, the finished yogurt product must contain live LAB inamounts 10 8 organisms/gat the time of manufacture (3), and the cultures must remain active at the end of the stated shelf life, as ascertained with the use of a specific activity test. In many modern societies, fermented dairy products make up a substantial proportion of the total daily food consumption. Furthermore, it has long been believed that consuming yogurt and other fermented milk products provides various health ben- efits (4). Studies fromthe 1990s on the possible health properties of yogurt added to this belief (1, 5). Probiotic therapy is based on the notion that there is such a thing as a normal healthy microflora, but normal healthy mi- croflora has not been defined except perhaps as microflora with- out a pathogenic bacterial overgrowth. The development of novel means of characterizing and modifying the gut microflora has opened up newperspectives on the role of the gut microflora in health and disease. Numerous studies suggested beneficial therapeutic effects of LAB on gut health. However, results have been inconsistent, which may be due to differences in the strains of LAB, routes of administration, and investigational procedures used in these studies. Several LAB species are currently used in the production of yogurt. This review focuses on the current evidence suggesting that yogurt and specific LAB species that are used for the fer- mentation of milk may or may not have valuable health- promoting properties or therapeutic effects on various gastroin- testinal functions and diseases. 1 Fromthe JeanMayer USDAHumanNutritionResearchCenter onAging at Tufts University, Boston. 2 Address reprint requests to SN Meydani, Nutritional Immunology Lab- oratory, JM USDA-HNRCA at Tufts University, 711 Washington Street, Boston, MA 02111. E-mail: simin.meydani@tufts.edu. Received October 3, 2003. Accepted for publication February 12, 2004. 245 Am J Clin Nutr 2004;80:24556. Printed in USA. 2004 American Society for Clinical Nutrition
b y
g u e s t
o n
M a r c h
2 ,
2 0 1 4 a j c n . n u t r i t i o n . o r g D o w n l o a d e d
f r o m
NUTRITIONAL VALUE OF YOGURT The nutrient composition of yogurt is based on the nutrient composition of the milk from which it is derived, which is af- fected by many factors, such as genetic and individual mamma- lian differences, feed, stage of lactation, age, and environmental factors such as the season of the year. Other variables that play a role during processing of milk, including temperature, duration of heat exposure, exposure to light, and storage conditions, also affect the nutritional value of the final product. In addition, the changes in milk constituents that occur during lactic acid fer- mentation influence the nutritional and physiologic value of the finished yogurt product. The final nutritional composition of yogurt is also affected by the species and strains of bacteria used in the fermentation, the source and type of milk solids that may be added before fermentation, and the temperature and duration of the fermentation process. B vitamins Dairy products have generally been considered an excellent source of high-quality protein, calcium, potassium, phosphorus, magnesium, zinc, and the B vitamins riboflavin, niacin, vitamin B-6, and vitamin B-12 (6). A much greater loss of vitamins than of minerals may occur during the processing of yogurt because vitamins are more sensitive to changes in environmental factors than are minerals. Some of the factors that are important during the processing of milk and that are known to have adverse effects on the vitamin content of dairy products in general include heat treatment and pasteurization, ultrafiltration, agitation, and oxi- dative conditions. In addition, bacterial cultures used during the fermentation process of yogurt can influence the vitamin content of the final product (6). LAB species do require B vitamins for growth, but some cultures are capable of synthesizing B vitamins (6). An example of a B vitamin that is utilized by LAB is vitamin B-12 (7, 8). Vitamins required for the growth of LABcultures vary fromone strain to another. Significant losses of vitamin B-12 can be cor- rected by the careful use of supplementary LABcultures that are capable of synthesizing vitamin B-12 (9). Folate is the best example of a B vitamin that some LAB species synthesize (10, 11). Depending on the bacterial strains used, the folate content of yogurt can vary widely, ranging from 4 to 19 g/100 g (8). The major form of folate present in milk is 5-methyl-tetrahydrofolate (12). In a recent study, bacterial iso- lates fromvarious species used for milk fermentation and yogurt productionwere examinedfor their abilitytosynthesize or utilize folate (11). S. thermophilus and Bifidobacteria were folate pro- ducers, whereas Lactobacilli depleted folate from the milk me- dia. Acombination of folate-producing cultures resulted in even greater folate content of the final fermented product. Further studies on the effect of changes in the vitamin B content of milk on fermentation would be of great practical significance. Lactose Dairy products and foods prepared with the use of dairy ingredi- ents are an exclusive source of the disaccharide lactose in human diets. Before absorption, lactose is hydrolyzed by the intestinal brush border -galactosidase (lactase) into glucose and galactose. These monosaccharides are absorbed and used as energy sources. Before fermentation, the lactose content of the yogurt mix gen- erally is 6% (3). One example of a significant bacteria-induced change that occurs duringthe fermentationprocess is the hydrolysis of 2030% of the disaccharide lactose to its absorbable monosac- charide components, glucose and galactose (2). In addition, a por- tion of the glucose is converted to lactic acid. Depending on other ingredients added, this hydrolysis results in lower lactose concen- trations in yogurt than in milk, which in part explains why yogurt is toleratedbetter thanmilkbypersons withlactose maldigestion(13 15). However, other factors also seem to play a role. For example, lactose-intolerant subjects exhibitedbetter tolerance for yogurt with arelativelyhighamount of lactosethanfor milkcontainingasimilar amount of lactose (13, 15). In another example, bacteria present in yogurt, such as L. bulgaricus and S. thermophilus, expressed func- tional lactase, the enzyme that breaks down lactose (16). This ex- pression may also contribute to better tolerance of lactose in yogurt than of lactose in milk by persons with lactose maldigestion (15). Protein The protein content of commercial yogurt is generally higher thanthat of milkbecause of the additionof nonfat drymilkduring processing and concentration, which increases the protein con- tent of the final product. It has been argued that protein from yogurt is more easily digested than is protein from milk, as bacterial predigestion of milk proteins in yogurt may occur (8, 17). This argument is supported by evidence of a higher content of free aminoacids, especiallyproline andglycine, inyogurt than in milk. The activity of proteolytic enzymes and peptidases is preserved throughout the shelf life of the yogurt. Thus, the con- centration of free amino groups increases up to twofold during the first 24 h and then doubles again during the next 21 d of storage at 7 C(18). Some bacterial cultures have been shown to have more proteolytic activity than do others. For example, L. bulgaricus was shown to have a much higher proteolytic activity during milk fermentation and storage than does S. thermophilus, as indicated by elevated concentrations of peptides and free amino acids after milk fermentation (19). During fermentation, both heat treatment and acid production result in finer coagulation of casein, which may also contribute to the greater protein digestibility of yogurt than of milk. Proteins in yogurt are of excellent biological quality, as are those in milk, because the nutritional value of milk proteins is well preserved during the fermentation process (20). Both the caseins and the whey proteins in yogurt are rich sources of all the essential amino acids, and the intestinal availability of nitrogen has been reported as being high (93%; 21, 22). Labeling of milk proteins with the stable isotope 15 N has made it possible to discriminate between exogenous and endogenous nitrogen fractions in serum after ingestion of 15 N-labeled milk or 15 N-labeled yogurt proteins. In a study of human subjects, Gaudichon et al (23) found that pro- teins from both milk and yogurt were rapidly hydrolyzed after ingestion, but the gastroduodenal transfer of dietarynitrogenwas slower when yogurt was fed than when milk was fed. Lipids Milk fat also goes through biochemical changes during the fermentation process. Minor amounts of free fatty acids are re- leasedas a result of lipase activity(3). Because most of the yogurt sold in the United States is of the low-fat and nonfat varieties, hydrolysis of lipids contributes little to the attributes of most yogurt products. However, yogurt has been shown to have a higher concentration of conjugated linoleic acid (CLA), a long-chain 246 ADOLFSSON ET AL
b y
g u e s t
o n
M a r c h
2 ,
2 0 1 4 a j c n . n u t r i t i o n . o r g D o w n l o a d e d
f r o m
biohydrogenatedderivative of linoleic acid, thandoes the milkfrom which the yogurt was processed (24). A fermented dairy product from India, referred to as dahi, has also been shown to have higher CLAcontent than does nonfermented dahi (25). The major sources of CLA in our diets are animal products from ruminants, in which CLA is synthesized by rumen bacteria. Increased consumption of dairy fat was shown to be associated with increased concentrations of CLAin both human adipose tissue (26) and human milk (27). It was hypothesizedthat biohydrogenationalsooccurs duringfermen- tationof milkandresultsinhigher concentrationsof CLAinthefinal product (28). CLA was reported to have immunostimulatory and anticarci- nogenic properties (29). In a recent study of breast and colon cancer cells, Kemp et al (30) showed that the anticarcinogenic properties of CLAmaybe due tothe abilityof some CLAisomers to inhibit the expression of cyclins and thus halt the progression of the cell cycle fromG1toSphase. Inaddition, CLAinducedthe expression of the tumor suppressor p53. Minerals In addition to being a good source of protein, yogurt is an excellent source of calcium and phosphorus. In fact, dairy prod- ucts such as milk, yogurt, and cheese provide most of the highly bioavailable calcium in the typical Western diet. Because of the lower pH of yogurt compared with that of milk, calcium and magnesium are present in yogurt mostly in their ionic forms. One of the major functions of calciumis the role it plays in bone formation and mineralization. The calcium requirements during growth, pregnancy, and lactation are increased. However, the aver- age calcium intake of women of childbearing age is consistently less than is recommended (31). In addition, calcium intake of women tends to fall even lower during the postmenopausal years (32). This is especially important for postmenopausal women, who are at increased risk of bone loss and osteoporosis. Dietary fiber has an adverse effect on calcium absorption, whereas lac- tose may enhance the absorption of calcium (33). In the rat model, calciumretention was greater with consumption of a diet in which lactose made up half the total carbohydrates ingested than with consumption of the control diet (34). Schaafsma et al (35), investigating the effect of dairy products on mineral ab- sorption by using rat models, reported that lactose enhances the absorption of calcium, magnesium, and zinc. Because yogurt has a lactose content lower than that of milk, the bioavailability of these minerals may be negatively affected, although the effect is likely to be small. The acidic pH of yogurt ionizes calcium and thus facilitates intestinal calcium uptake (36). The low pH of yogurt also may reduce the inhibitory effect of dietary phytic acid on calcium bioavailability. Vitamin D plays a major regulatory role in in- testinal calcium absorption. The active, saturable, transcellular route of calcium absorption in the duodenum and proximal jeju- num requires calbindin-D, a vitamin Ddependent calcium- binding protein (37). In the United States, milk and infant for- mula are fortified with vitamin D, and hence they serve as good dietary sources, with 2.5g (100 IU) vitamin D/237-mLserving. However, other dairy products, such as yogurt, typically are not fortified with vitamin D. Few studies have investigated the effect of yogurt-derived calcium on bone mineralization in animals (34, 38). Kaup et al (34) reported that yogurt-fed rats showed greater bone mineral- ization than did rats fed a diet containing calcium carbonate. These studies may suggest that the bioavailability of calcium in yogurt is greater and yogurt may increase bone mineralization more than do nonfermented milk products. However, there are currently no published studies that show a superior effect of yogurt on bone mineralization in human subjects. MECHANISTIC RATIONALE FOR POTENTIAL BENEFITS OF YOGURT ON GUT FUNCTION AND HEALTH It has been suggested that yogurt and LAB contribute to sev- eral facets of gastrointestinal health: the makeup of the gastro- intestinal flora, the immune response, and laxation. Gut microflora Lactobacilli are among the components of microbial flora in both the small and large intestines. The ability of nonpathogenic intestinal microflora, such as LAB, to associate with and bind to the intestinal brush border tissue is thought to be an important attribute that prevents harmful pathogens from accessing the gastrointestinal mucosa (39). For LAB to have an effect, they must adapt to the host intestinal environment and be capable of prolonged survival in the intestinal tract (4043). LAB survival is influenced by gastric pH as well as by exposure to digestive enzymes and bile salts (42), and LAB species differ in their ability to survive in the gastrointestinal environment (43). When 4 strains of Bifidobacterium (B. infantis, B. bifidum, B. adolescentis, and B. longum) were compared, B. longumwas the most resistant to the effects of gastric acid (44). Bifidobacterium animalis was reported to have a high survival rate during intes- tinal transit in human subjects (45). The effect of feeding yogurt fermented with S. thermophilus, L. bulgaricus, and Lactobacillus casei on the fecal microflora of healthy infants aged 1018 mo was investigated by Guerin- Danan et al (46). Whereas the number of infants with fecal Lactobacillus increased after the feeding, the total numbers of anaerobes, Bifidobacteria, bacteroides, and enterobacteria were not affected by yogurt intake. In a group of elderly patients with atrophic gastritis and hypochlorhydria, Lactobacillus gasseri survived passage through the gastrointestinal tract, but S. ther- mophilus and L. bulgaricus were not recovered (43). Bifidobac- terium sp has also been shown to survive passage through the gastrointestinal tract: fecal concentrations were detectable for 8 d after the cessation of intake (47). Another important factor that limits the survival of lactobacilli within the upper gastrointestinal tract is the inherent ability of the organisms to adhere to intestinal epithelial cells (42). With the use of scanning electron microscopy, Plant and Conway (48) screened 16 strains of Lactobacillus for their capacity to associ- ate with Peyers patches and the lymphoid villous intestinal tis- sues in mice. Two of the 16 strains investigated, Lactobacillus acidophilus and L. bulgaricus, are of interest because they relate to yogurt. It was found, in both in vitro and in vivo models using BALB/c mice, that L. bulgaricus did not associate with Peyers patches or with the lymphoid villous intestinal tissues. L. aci- dophilus had a low degree of association with Peyers patches and no association to the lymphoid villous intestinal tissue. Nev- ertheless, the authors stated that the strains of Lactobacillus tested showed high rates of survival when Lactobacillus was administered orally. YOGURT AND GUT FUNCTION 247
b y
g u e s t
o n
M a r c h
2 ,
2 0 1 4 a j c n . n u t r i t i o n . o r g D o w n l o a d e d
f r o m
The ability of LABto decrease the gastrointestinal invasion of pathogenic bacteria has also been described (39, 49). Bernet et al (39) reported a dose-dependent L. acidophilusmediated inhibi- tion of the adherence of enteropathogenic Escherichia coli and Salmonella typhimurium to the enterocyte cell-line Caco-2. In addition, L. acidophilus inhibited the entry of E. coli, S. typhi- murium, and Yersinia pseudotuberculosis into Caco-2 cells. In another report (49), the same authors describedsimilar inhibitory effects when 2 different strains of Bifidobacteria (B. breve and B. infantis) were used. Inaddition, long-termfeedingof yogurt does not result ina significant change inthe results of breath-hydrogen tests, which indicates the absence of a significant change in the intestinal survival of the yogurt organisms (50). Furthermore, it is possible that the ability of LABto compete with pathogens for adhesion to the intestinal wall is influenced by their membrane fluidity. This possibility was suggested by studies indicating that the type and quantities of polyunsaturated fatty acids in the ex- tracellular milieu influence the adhesive properties of LABto the epithelium (51, 52). Gut-associated immune response The mucosal lymphoid tissue of the gastrointestinal tract plays an important role as a first line of defense against ingested patho- gens. The interactions of LABwith the mucosal epithelial lining of the gastrointestinal tract, as well as with the lymphoid cells residing in the gut, have been suggested as the most important mechanism by which LAB enhances gut immune function. Sev- eral factors have been identified as contributing to the immuno- modulating and antimicrobial activities of LAB, including the production of low pH, organic acids, carbon dioxide, hydrogen peroxide, bacteriocins, ethanol, and diacetyl; the depletion of nutrients; and competition for available living space (1, 5, 53). The gastrointestinal tract is a complex immune system tissue. The mainsite of the mucosal immune systeminthe gut is referred to as gut-associated lymphoid tissue (GALT), which can be di- vided into inductive and effector sites. In the small intestine, the inductive sites are in the Peyers patches, which consist of large lymphoid follicles in the terminal small intestine. The best- defined effector component of the mucosal adaptive immune system is secretory immunoglobulin A (sIgA). sIgA is the main immunoglobulin of the humoral immune response, which to- gether with the innate mucosal defenses provides protection against microbial antigens at the intestinal mucosal surface (54). In a healthy person, sIgAinhibits the colonization of pathogenic bacteria in the gut, as well as the mucosal penetration of patho- genic antigens. At least 80% of all the bodys plasma cells, the source of sIgA, are located in the intestinal lamina propria throughout the length of the small intestine. IgA is the most abundantly produced immunoglobulin in the human body. The productionof intestinal sIgArequires the presence of commensal microflora (55), which indicates that the production of intestinal sIgA is induced in response to antigenic stimulation. It is not yet clear, however, how lamina propria B cells are activated to be- come IgA-secreting plasma cells or howthe intestinal microflora influence this process. Most studies on the effect of fermented milk or specific LAB on gut immune function have centered on their immune adjuvant effects in the gut. The ability of LAB to modulate IgA concentrations in the gut has also been the subject of several studies. Orally administered L. acidophilus and L. casei and the feeding of yogurt increased both IgAproduction and the number of cells secreting IgAin the small intestine of mice in a dose-dependent manner (5). Simi- larly, a report by Puri et al (56) indicated that S. typhimurium- induced serum IgA concentrations were significantly higher in mice fed yogurt over a period of 4 wk than in milk-fed control mice. This report suggests that the IgAsecretedbythe challenged intestinal Bcells enters the circulation and increases the concen- trations of IgA in the serum. Thus the IgA-enhancing effect of yogurt intake may have both an effect on the gut and a systemic effect. The same study also showed that intestinal lymphocytes frommice fed yogurt had a higher mitogen-induced proliferative response after a challenge with S. typhimurium than did those from control-fed mice. In a study using human subjects, Link-Amster et al (57) showed that the specific anti-IgA titer to S. typhimurium was 4 times greater in subjects fed fermented milk containing L. aci- dophilus than in control subjects fed diets without fermented milk. Total sIgA concentrations also increased in subjects fed fermented milk. Macrophages play an important role as a part of the innate immune response in the gut, and they represent one of the first lines of nonspecific defense against bacterial invasion. The ef- fects of feeding milk fermented with either L. casei or L. aci- dophilus or both on the specific and nonspecific host defense mechanisms in Swiss mice were investigated by Perdigon et al (58). They showed that feeding milk fermented with L. casei, L. acidophilus, or both for 8 d increased the in vitro and in vivo phagocytic activity of peritoneal macrophages and the produc- tion of antibodies to sheep red blood cells. The activation of the immune system began on day 3, peaked on day 5, and decreased somewhat on day 8 of feeding. Phagocytic activity was further boosted in mice given a single dose of fermented milk on day 11 of feeding. Modulation of cytokine production by yogurt and LAB has also been the focus of several studies. In addition to interleukin (IL)-1 and tumor necrosis factor (TNF) , which are mainly produced by macrophages, Tlymphocytes are the source of most cytokines investigated in those reports. T cells are frequently classifiedinto2categoriestype 1(Th1) andtype 2(Th2) helper T cells. On activation, these cells produce 2 diverse patterns of cytokines (59). Th1 cells are the main producers of interferon- (IFN-) and IL-2, and Th2 cells produce IL-4, IL-5, IL-6, and IL-10. The Th1 cytokines boost cell-mediated immunity, and the Th2 cytokines augment humoral immunity. IFN- plays a criti- cal role in the induction of other cytokines and in mediation of macrophage and natural killer cell activation. Several reports indicated that consumption of yogurt or intake of LABby themselves modulates the production of several cytokines, such as IL-1, IL-6, IL-10, IL-12, IFN-, and TNF- (6063). Moreover, the production of IFN- in an in vitro culture system using human lymphocytes was reported to be greater with cultures in the presence of LAB (L. bulgaricus and S. thermophilus) than with those without LAB(64). Yogurt containing live L. bulgaricus andS. thermophilus was alsoreportedtoaugment IFN-production by purified T cells from young adults after 4 mo feeding (62). Effects of yogurt consumption on the modulation of cytokine production in the human gastrointestinal tract, whether by cells of the GALT or by others, have not been investigated. These types of studies, although feasible with the use of biopsy samples from the intestines of healthy subjects (65), are difficult to carry out, and good animal models currently do not exist. 248 ADOLFSSON ET AL
b y
g u e s t
o n
M a r c h
2 ,
2 0 1 4 a j c n . n u t r i t i o n . o r g D o w n l o a d e d
f r o m
Even though cytokines play diverse roles in regulating immune functions, some cytokines, eg, IL-1, IL-6, and TNF-, have been given more attention than others because they have traditionally been classified as proinflammatory and as such are known to be associated with inflammatory conditions such as Crohn disease and ulcerative colitis (66). Another diverse family of immune modulators that play important roles in the health of the gastrointestinal tract consists of chemokines and their recep- tors (67). Currently, only limited data have been published on the effect of yogurt or its components on chemokine modulation in the gastrointestinal tract. The effects of different strains of Lac- tobacillus on chemokine production by the intestinal epithelial cell-line, HT-29, were investigated by Wallace et al (68). All 3 LABspecies investigatedL. acidophilus, Lactobacillus rham- nosus, and Lactobacillus delbrueckiihad suppressive effects on the production of 2 chemokines, RANTES (a member of the IL-8 superfamily of cytokines) and IL-8, by activated HT-29 cells. As is the case with proinflammatory cytokines, these che- mokines are necessary for normal immune function. However, a high production of these chemokines during an inflammatory condition is believed to exacerbate the inflammatory response. Laxation Few reports have discussed the effects of yogurt and LAB on laxation. In the studies published, however, both significant ef- fects (G Wilhelm, unpublished observations, 1993; 69) and no effects (70) of yogurt or LAB on laxation and gastrointestinal transit time were described. Strandhagen et al (69) reported that the transit time for 50% (t50) of gastric content was significantly greater for ropy milk, an L. bulgaricus and S. thermophilusfermented milk product indigenous to Sweden, than for unfermented milk. Another study showedthat milkfermentedwithL. bulgaricus andS. thermophi- lus reducedintestinal transit time inhumansubjects withhabitual constipation (G Wilhelm, unpublished observations, 1993). In the same study, subjects consuming fermented milk also had improved bowel function. The number of defecations increased from 3/wk during a control period to 7/wk when fermented milk was consumed. When milk fermented with L. acidophilus was consumed, the number of defecations increased further to 15/wk. Studies were conducted of the effects of a commercially avail- able yogurt fermented with B. animalis on orofecal gut transit time (71, 72). In a double-blind, randomized, crossover design, B. animalis reduced the colonic transit time in a group of healthy women aged 1845 y (72). Likewise, in a group of elderly subjects experiencing lengthy orofecal gut transit time but oth- erwise free of any gastrointestinal pathology, B. animalis intake provided led to a significant reduction in transit time (71). Thus, the effect of LAB ingestion on orofecal gut transit time appears to be dependent on the bacterial strain used and the population being studied. YOGURT AND DISEASES OF THE GASTROINTESTINAL TRACT Lactase deficiency and lactose maldigestion Lactase deficiency among adults is the most common of all known enzyme deficiencies. More than half of the worlds adult populationis lactose intolerant. Indevelopmental terms, this may not necessarily be considered abnormal, because humans are the only known mammal in whom lactase activity in the small intestine is sustained after weaning. In the case of lactose mal- digestion, undigested lactose remains in the intestinal lumen, and, as it reaches the colon, it is fermented by colonic bacteria. Byproducts of this process include short-chain fatty acids such as lactate, butyrate, acetate, and propionate. These fatty acids as- sociate with electrolytes and lead to an osmotic load that can induce diarrhea. Furthermore, fermentation of lactose by colonic bacteria produces methane, hydrogen, andcarbondioxide. These gases may stay in the lumen and eventually will both be excreted as flatus, diffusing into the circulation, and be exhaled via the lungs. Exhaled hydrogen after a lactose load has been used as an indirect but measurable indicator of lactose maldigestion. In addition to lactose, some sources of dietary fiber and other un- absorbed carbohydrates can serve as substrates for colonic fer- mentation that results in increased hydrogen production. Inability to digest lactose varies widely among ethnic and geographic populations (73, 74). In the United States, the prev- alence of primary lactose intolerance in adults is 53% among Mexican Americans, 75% among African Americans, and 15% among whites. The prevalence among adults in South America and Africa is 50% and that in some Asian countries is close to 100%. Lactose intolerance varies greatly between European countries, from 2% prevalence in Scandinavian adults to 70% among Southern Italian adults (74). Lactose maldigestionmaydevelopsecondarytoinflammation or as a result of functional loss of the small intestinal mucosa (14), which can result from conditions such as Crohn disease, celiac sprue, short bowel syndrome, or bacterial and parasitic infec- tions. In addition, lactose maldigestion may develop as a conse- quence of severe protein calorie malnutrition. The disorder is clinically expressed by symptoms of abdominal cramps, diar- rhea, and flatulence after milk ingestion. However, most persons who have symptoms of lactose intolerance can endure small amounts (210 g) of lactose in a meal without becoming symp- tomatic (14). It is well known that, for many lactose-intolerant people, fer- mented milk products are better accepted than are unfermented milk products. There may be more than one reason for this. During fermentation of milk, lactose is partially hydrolyzed, which results in a lower lactose content in yogurt than in milk (2). However, this reduction in lactose may not be significant, be- cause milk solids are usually added during processing. The greater tolerance of lactose from yogurt than of that from milk among lactose-intolerant subjects may be due to the endogenous lactase activity of yogurt organisms (13, 15, 75). Kolars et al (15) used a series of breath hydrogen tests as well as a subjective assessment to ascertain whether subjects who were identified as lactose-intolerant digested and absorbed lactose in yogurt better than they digested and absorbed lactose in milk. The area under the curve for breath hydrogen was smaller after yogurt consump- tion than after consumption of milk or lactose in water, which indicates better digestion and absorption of lactose from yogurt than of that from either milk or lactose in water. Subjective assessment by the subjects in the study of Kolars et al also indicated that lactose in yogurt was better tolerated than the same amount of lactose from milk or in water. Using breath hydrogen measurement, Savaiano et al (75) investigated the effects of 3 varieties of cultured milk products on the digestion of lactose by 9 lactase-deficient human subjects. When yogurt, cultured milk (buttermilk), and sweet acidophilus milk were compared, yogurt YOGURT AND GUT FUNCTION 249
b y
g u e s t
o n
M a r c h
2 ,
2 0 1 4 a j c n . n u t r i t i o n . o r g D o w n l o a d e d
f r o m
had the most beneficial effect on lactose digestion in these sub- jects. Lactase activity and the number of surviving LAB were significantly reduced when the yogurt was pasteurized. The enzyme activity of lactase is generally stable in response toenvironmental factors. For example, it was shownthat thelactase activityof yogurt was preservedandevenincreasedwhentheyogurt was subjected to an environment that simulated the temperature and lowpHvalues of the gut (15). As suggested by the authors, this study supports the notion that lactose in yogurt is autohydrolyzed once it is in the jejunal environment. Other studies reported that lactase activity is less stable in response to acidic environment. Pochart et al (76) reportedthat lactaseactivityinyogurt decreasedby 80% at a pH of 5.0 in an in vitro model. However, heating yogurt does significantly decrease lactase activity, which indicates that yogurt that has been heat treated is not as beneficial for lactose-intolerant persons is yogurt contain- ing live and active cultures. Thus, there is a growing body of evidence that yogurt containing live and active cultures is better tolerated by lactose malabsorbers than are heat-treated fer- mented milks (50). During the fermentation process, the amount of lactose present in yogurt is reduced. The lactose content also varies withthe durationof storage after fermentation. Inaddition, the bacterial lactase activitycorresponds withthe survival time of lactobacilli after ingestion. The enhanced digestion of lactose is explained partly by the improved lactase activity after yogurt ingestion and partly by other enzymatic functions, such as the activity of the lactose transport system (permease) that allows lactose to enter the probiotic cell (77, 78). Furthermore, animal studies have suggested that LAB may induce lactase activity of the gut intestinal endothelial cells (79). Astudy by Martini et al (80) supports the microbial mediation of lactase activity in the gastrointestinal tract. Those authors showed that lactase activity in yogurt was stable at pH 4.0, but that microbial cell disruption resulted in 80% loss of lactase activity and a twofold increase in lactose malabsorption in a group of lactose maldigesters. Although the organisms that make up the live cultures in yogurt are recognized as having functional lactase activity and as contributing to the digestion of lactose, their survival in the gastrointestinal tract is short. On average, significant numbers survive for 1 h after ingestion (15, 50). Regardless of this somewhat limited survival time, the beneficial effect of LAB on lactose digestion in those suffering from lactose intolerance is now widely accepted. Diarrheal diseases Diarrhea is a commonproblemamongchildrenworldwide and has been reported to contribute substantially to pediatric physi- cian visits and hospitalizations in the United States (81). Since the early 20th century, it has been hypothesized that live bacterial cultures, such as those used for the fermentation of dairy prod- ucts, may offer benefits in preventing and treating diarrhea (4). A recent meta-analysis of randomized, controlled studies by Van Neil et al (82) found that therapy using Lactobacillus strains offered a safe and effective means of treating acute infectious diarrhea in children. Both the duration and frequency of diarrheal episodes were reduced when compared with those in control subjects. The benefit of Lactobacillus therapy was seen in diarrheal diseases caused by various pathogens. The effect of supplementing formulawithB. bifidumandS. thermophilus onpreventingtheonset of acute viral diarrhea in infants was examined in a double-blind, placebo-controlledtrial (83). Theinfants receivingbacterial therapy developed diarrhea and shed rotavirus less than did the infants fed the control formula. Evidence of the beneficial effect of LABonthe occurrence of diarrhea of bacterial origin is more contradictory be- cause both benefits (84, 85) and no effects (86, 87) of feeding LAB were reported. Several studies investigatedthe effects of probiotic bacteria on diarrhea associated with the use of antibiotics. The most likely cause of diarrhea associated with antibiotic use is the negative influence of antibiotics on the bacterial steady state of the intes- tines (88). Most cases of antibiotic-associated diarrhea are mild, and they end shortly after antibiotic therapy is discontinued. A less common but more serious type of antibiotic-associated di- arrhea is due to antibiotic-mediated overgrowth of pathogenic bacterial species such as Clostridium difficile that is associated with pseudomembranous colitis (89). A recent meta-analysis evaluated the ability of several differ- ent probiotic LAB species to prevent antibiotic-associated diar- rhea (90). Of the 9 studies that were included in the analysis, 4 used Lactobacilli strains or a combination of Lactobacilli and Bifidobacteria (9194). Of those 4 studies, 2 showed a signifi- cant benefit of probiotic use in comparison with placebo (93, 94). The authors concluded that probiotic bacteria supplied in cap- sules or as yogurt-based products may be useful in preventing antibiotic-associated diarrhea. However, none of these studies provide evidence for a role of probiotic bacteria in the treatment of such diarrhea. The mechanisms by which LAB may provide a beneficial effect against some forms of diarrheal disease are unknown. It has been suggested that the beneficial effect may stem from the ability of LABto reestablish the intestinal microflora, to increase the intestinal barrier by competing with pathogenic bacteria for adhesion to the enterocytes, or to increase mucosal IgAresponse to pathogens. Colon cancer According to the National Cancer Institute, cancer of the colon is the second leading cancer diagnosis among both women and men in the United States (95). Colon cancer is also the second most common cause of cancer death. Risk factors for colorectal cancer include both genetic and environmental factors, and sev- eral reports have suggested that interactions between dietary factors, colonic epithelium, and intestinal flora are central to the development of colon cancer. The role of diet in the etiology of cancer has been given greater attention in recent years. Although the relation between colon cancer and certain food constituents, such as fiber and fat, gen- eratedthe most interest, the possibilitythat fermenteddairyprod- ucts may protect against tumor formation in the colon was also investigated. Epidemiologic evidence suggests a negative corre- lation between the incidence of certain cancers, including colon cancer, and the intake of fermented dairy products (96). More- over, fermented dairy products or the bacteria used for milk fermentation were shown to have an effect on colon cancer and certain other tumors in murine models of carcinogenesis (97 100). However, a number of animal studies investigating the effect of various strains of LABon colon carcinogenesis showed inconsistent results. Wollowski et al (100) investigatedthe protective effect of several strains of LAB, traditionally used for milk fermentation, against 1,2-dimethylhydrazine (DMH)induced colon carcinogenesis in 250 ADOLFSSON ET AL
b y
g u e s t
o n
M a r c h
2 ,
2 0 1 4 a j c n . n u t r i t i o n . o r g D o w n l o a d e d
f r o m
rats. Oral treatment with L. bulgaricus for 4 d protected against DMH-induced DNAdamage in the colon. In contrast, there was no protective effect when S. thermophilus was administered. The au- thors did not ascertain the mechanisms of protection by L. bulgari- cus, but theyspeculatedthat thiol-containingbreakdownproductsof proteins that result fromtheproteolyticactivityof L. bulgaricus may have produced the effect. Ina previous studyusinga similar DMH-inducedcoloncancer model in rats, Shackelford et al (99) showed that milk fermented with L. bulgaricus resulted in greater survival than did nonfer- mented milk. However, in contrast to the findings of Wollowski et al (100), L. bulgaricus-fermented milk did not reduce the number of rats that developed colon tumors, whereas S. thermophilus-fermented milk did do so (99). In a study using azoxymethane to induce aberrant crypt foci in the colon of rats, no significant effects were seen with either B. longumor L. casei (101). Those authors did, however, observe a protective effect of L. acidophilus and inulin, but only when the total fat content of the diet was increased. Using a colon carcinoma cell culture system, Ganjam et al (102) isolated a yogurt fraction that decreased cell proliferation, as ascertained with the use of thymidine incorporation. Cell pro- liferation was not inhibited in response to a similarly isolated milk fraction or to lactic acid. Elevated activity of several bacterial fecal enzymes, some of which are involved in the metabolism of genotoxic nitrates, was associated with an increased risk of colon cancer (103, 104). The activity of these enzymes can be altered by diet or antibiotic intake (10, 105). L. acidophilus (106) and L. gasseri (43) were shown to reduce the fecal enzyme activity of nitroreductase, azoreductase, and -glucuronidase in humans, with a reduction by 50%or 75%in the activities of these enzymes during a period of Lactobacilli feeding. Likewise, Guerin-Danan et al (46) re- ported that 1018-mo-old infants fed yogurt fermented with S. thermophilus, L. bulgaricus, and L. casei had lower fecal -glucuronidase activity than did a similar group of infants fed milk or yogurt not fermented with L. casei. The mechanism by which LAB may have an effect on colon carcinogenesis is currently unknown. Some of the mechanisms that maybeinvolvedincludeenhancement of thehosts gut immune response, suppression of harmful intestinal bacteria, sequestration of potential mutagens, production of antimutagenic compounds, reduction of pHconcentrations in the colon, and alteration of other physiologicconditions(107). Furthermore, it wasshownbyPedrosa et al (43) that the feeding of yogurt or Lactobacillus reduced fecal enzymes, which convert procarcinogens to carcinogens, such as azoreductase and nitroreductase. Inflammatory bowel disease Inflammatory bowel disease (IBD) is a term used for certain chronic immunemediated conditions of the intestinal tract. These chronic diseases include Crohn disease and ulcerative colitis, conditions that have comparable symptoms but that affect the digestive tract in very different ways (66). Ulcerative colitis involves inflammation of the colon and rectumand not that of the upper gastrointestinal tract, whereas Crohn disease can affect the upper intestinal digestive tract andthus canleadtomalabsorption of both macronutrients and micronutrients. The etiologies of these diseases are unknown, but studies suggest that the intestinal microflora play a crucial pathogenic role (108). This notion is supported by animal models of Crohn disease, in which the presence of intestinal microflora is absolutely required for the development of disease. Proinflammatory cytokines, particularly TNF-, have also been recognized as playing a central role in the pathogenesis of Crohn disease. However, despite earlier hopes, the results from studies using TNF- antagonists were disappointing, and there were some reports of severe complications (109). Nevertheless, reducing the production or effect of TNF- (or both) in Crohn disease patients is belived to be beneficial. Bourrel et al (63) reported that, when inflamed intestinal mucosa from a group of Crohns disease patients was cocultured in the presence of L. casei or L. bulgaricus, expression and release of TNF- by intraepithelial lymphocytes were reduced. Normally, a healthy mucosal barrier provides a first defense mechanism against both the intestinal microflora and invading pathogens. It has been suggested that the proportions of different intestinal microflora are altered in patients with IBD. For exam- ple, colonic biopsy specimens have shown lower concentrations of Lactobacillus and lower fecal concentrations of both Lacto- bacillus and Bifidobacteriumspecies in patients with Crohn dis- ease than in healthy subjects (110). This disturbance in intestinal flora may increase the opportunity for colonization of pathogens and bring about a subsequent proinflammatory response. In the case of IBD, a defective mucosal barrier allows for in- creased uptake of antigens and proinflammatory mediators origi- nating fromluminal bacteria. It has been reported that patients with IBDhavediminishedmucosal protectionasaresult of changesinthe compositionandthicknessof themucosal layer andalterationsinthe glycosylationstatus of mucosal glycoproteins (111). These changes inthe intestinal mucosa are alsoassociatedwithdecreasedintestinal IgA activity and increased IgG activity, which coincides with re- duced state of protection and a proinflammatory condition. With weakened mucosal barrier and thereby increased adherence of bac- terial pathogens to the mucosa, sustained inflammation results, and that leads to further damage to the gut mucosa. In recent years, immunosuppressive and immunomodulating therapies, such as the steroids usedsince the 1960s, have become more andmore frequent in the treatment of these conditions. Although efficacious, these types of drugs can increase the prevalence of opportunistic infec- tions as well as the severity of any underlying infection that may be present (112). Other side effects of these treatments may include hepatotoxicity, fibrosis, lymphoma, and pathologic suppression of bone marrow function. The role of beneficial intestinal microflora in the prevention of intestinal inflammation was investigated by using gene-targeted IL-10 knockout (IL-10 / ) mice (113, 114). These IL-10defi- cient mice spontaneously develop ileocolitis with many similar- ities to Crohn disease in humans. Furthermore, affected mice respond favorably to immunosuppression or immunomodula- tory drugs that are similar to those used to treat human IBD. The immunoregulatory activity of IL-10 has been studied exten- sively. It is nowwell established that IL-10 plays a role in down- regulating both the synthesis of inflammatory cytokines and the presentation of antigens. Thus, IL-10 has been suggested for use as an immunomodulator for the treatment of Crohn disease. Targeted in vivo delivery of IL-10 to the affected intestinal ep- ithelium by using genetically engineered Lactococcus lactis has shown great promise in 2 mouse models of IBD (114). Madsen et al (113) found that IL-10 / mice had increased adherence of luminal bacteria to the mucosal layer in the colon YOGURT AND GUT FUNCTION 251
b y
g u e s t
o n
M a r c h
2 ,
2 0 1 4 a j c n . n u t r i t i o n . o r g D o w n l o a d e d
f r o m
that preceded the development of colitis. This occurred in par- allel to decreased numbers of luminal Lactobacillus. When the concentrations of Lactobacillus in the gastrointestinal lumen were restored by rectal delivery of Lactobacillus reuteri or by oral lactulose therapy, colitis was attenuated. The concentrations of adherent and translocated bacteria in the mucosal wall also were reduced. Another benefit of LAB in Crohn disease may be due to the stimulation of the IgA response. A report by Malin et al (115) suggests that oral bacteriotherapy using L. casei can restore antigen-specific IgA immune response in persons with Crohn disease. In a previous study fromthe same laboratory (116), oral administration of L. casei to patients with viral gastroenteritis promoted antigen-specific IgA responses and shortened the pa- tient diarrhea. Although experimental evidence exists indicating beneficial effects of LABon Crohn disease and ulcerative colitis, the exact mechanismthrough which LABspecies antagonize the progres- sion of these diseases is poorly understood. The exact etiology of IBD is also unknown, but it is likely that, in susceptible persons, IBDresults froman ongoing inflammatory response, which may be due to a defect in both the regulation of the mucosal proin- flammatory response and the function of the intestinal epithe- lium. Currently, evidence suggests that yogurt and LAB have modest clinical benefits and are safe for use in patients with these conditions. Further studies are required to ascertain whether yo- gurt is beneficial as a prophylactic or a therapeutic regimen for IBD (or both) and to establish exactly which mechanisms are involved. Helicobacter pylori It has only been 20 y since Helicobacter pylori, a gram- negative, spiral-shaped bacterium that is found in the gastric mucous layer or adherent to the epithelial lining of the stomach, was discovered (117). H. pylori relies on the ammonia- producing surface protein urease for adherence and colonization to the gastric epithelium. Urease allows H. pylori to survive by neutralizing the acidic gastric environment (118). H. pylori pro- duces catalase, which may play a role in protecting the bacteria from free radicals that are released by activated leukocytes. H. pylori infection is associated with a massive infiltration of neu- trophils into the gastric wall and local production of IFN-, proinflammatory cytokineseg, TNF-, IL-1, and IL-6and the chemokine IL-8. Infection with H. pylori is now known to play a role in peptic ulcer disease, chronic gastritis, gastric adenocarcinoma, and mucosa-associated lymphoid tissue lymphoma. The association between duodenal ulcer disease and H. pylori is also well doc- umented: H. pylori infection is reported in 90% of duodenal ulcer patients (119). Treatment of this infection involves the use of proton pump inhibitors, often in combination with antibiotics. However, the use of antibiotics to treat H. pylori infection has been associated with adverse effects and frequently leads to resistance to antibiotic therapy. Several in vitro and animal studies have shown reduced via- bility of H. pylori and less adhesion of the bacteria to human intestinal mucosal cells after treatment with various Lactobacil- lus strains (120). In series of in vitro assays, Midolo et al (121) showed that the growth of H. pylori was inhibited by lactic acid in a pH-independent manner. They also found that 6 strains of L. acidophilus and L. casei inhibited the growth of H. pylori, whereas B. bifidus and L. bulgaricus did not. The inhibitory effect correlated with the concentrations of lactic acid produced by the LAB examined. In another study, Coconnier et al (122) reported that conditioned media fromL. acidophilus reduced the viability of H. pylori in vitro, independent of lactic acid concen- trations. In addition, the adhesion of H. pylori to human mucose- creting HT-29 cells decreased. Several in vitro studies were con- ducted to ascertain whether the effects of LAB on H. pylori survival and function are due to lactic acid or to other antibac- terial products generated by LAB, such as bacteriocins. Of the several bacteriocins tested, lacticins produced by Lactoc. lactis were shown to have the greatest anti-Helicobacter activity when used against several strains of H. pylori (123). Studies that indicate promising inhibitory effects of LAB on H. pylori survival andfunctioninvitrowere extendedtoinvivostudies using human patients. Armuzzi et al (124) reported that, when 120 asymptomatic subjects who were positive for H. pylori infection received an L. casei strain GG supplement over a 14-d period in addition to a standard 1-wk antibiotic therapy regimen, the eradica- tion of H. pylori was faster than that in control subjects. Although promising results have been reported, the effects of LAB on H. pylori infection in humans remain ambiguous. For example, L. acidophilus and L. gasseri were both shown to decrease H. pylori infection, as indicated by reduced [ 13 C] urea breathtest values (125, 126), andtherapywithL. acidophilus was shown to reduce gastric mucosal inflammation (125). However, gastric biopsies did not showeradication of H. pylori. Similarly, Cats et al (127) reported that viable L. casei was required to inhibit the growth of H. pylori in vitro, but only a slight nonsig- nificant trend was observed toward an in vivo suppressive effect of an L. casei-supplemented milk drink. Allergic reactions The effects of yogurt and LAB on allergic reactions in the gastrointestinal tract have received some interest (128, 129). It was reported that a delay in the development of Bifidobacterium and Lactobacillus in the gastrointestinal microflora is a general finding in children with allergic reactions (128). Isolauri (130) reported data suggesting that Lactobacillus GG can be used to prevent food allergies. Heat treatment was suggested as a way of reducing the ability of milk proteins to cause allergic reactions, which would make milk a more suitable source of protein for persons with an im- munologic sensitization to cow milk protein (131). However, Kirjavainen et al (129) used a randomized double-blind design to investigate in a recent study the effects of heat-inactivated and viable L. rhamnosus GG on infants with atopic eczema and cow milk allergy. Milk formula supplemented with viable but not heat-inactivated L. rhamnosus GGsignificantly improved atopic eczema and subjective symptoms of cowmilk allergy in subjects in comparison with the control group. These results suggest that, in persons with cow milk allergy, the presence of viable LAB may provide benefits that outweigh the possible detrimental effects that undenatured milk proteins may have on milk al- lergy. Furthermore, the immunologic response to native milk proteins may differ from that to heat-denatured milk proteins. A recent study using a rat model showed that heat-denaturated -lactoglobulin induced a local mucosal inflammatory response, whereas native -lactoglobulin induced an IgE-mediated systemic response (132). Heat denaturation is likely to result in 252 ADOLFSSON ET AL
b y
g u e s t
o n
M a r c h
2 ,
2 0 1 4 a j c n . n u t r i t i o n . o r g D o w n l o a d e d
f r o m
conformational changes that expose or hide (or both) epitopes and lead to the activation of different subpopulations of immune cells and thus to different end results. The mechanisms of the protective effects of LAB on allergic reactions are not known. A proinflammatory response in the gut mucosa that is induced by food allergens may impair the function of the intestinal barrier. It is possible that LAB may prevent allergic reactions by having a protective effect on the function of the intestinal barrier, although the mechanismof such an effect is poorly understood. A more direct link between the function of GALTand allergic responses is also possible. One of the primary mechanisms of active cellular suppression of proinflammatory events in the gut after antigen-specific triggering is the secretion of suppressive cytokines, such as transforming growth factor and IL-10. Transforming growth factor is produced by both CD4
and CD8
GALT-derived T cells and is an important
mediator of the active suppression component of oral tolerance. Furthermore, IL-4mediated isotype switching of immunoglob- ulin from IgM to IgE and IgE-dependent degranulation of mast cells has been shown to be involved in the pathogenesis of food allergyrelated enteropathy (133). Yogurts LAB are known to enhance the production of IFN- (62, 134), which acts to inhibit isotype switching to IgE. IgE- mediated hypersensitivity reaction, also known as type 1 allergy, is triggered by the cross-linking of antigens with IgE antibodies that are bound to Fc receptors on mast cells. It was reported that L. casei inhibited antigen-induced IgE production by mouse splenocytes (135). In addition, production of the immunosup- pressive cytokine IL-10 is induced by LAB (60). A combination of enhancing and suppressive effects is the most likely mechanism by which LAB may have their effects. However, the ways in which LABor other components of yogurt influence the productionof these immunoregulatorycytokines in the gut remain to be elucidated, as do the possible mechanisms of LAB-mediated protection. SAFETY Although the safe use of nonsporing anaerobic LAB in fer- mented foods is widespread and has a long history, there have been occasional reports associating LABwith clinical infections (53, 136) because benign microorganisms have been shown to be infective when a patient is severely debilitated or immunosup- pressed (137, 138). Some of the diseases that have been associ- ated with LAB infection include septicemia, infective endocar- ditis, and dental caries. Very rarely, cases of lactobacillemia have been reported in patients with severe underlying illness, many of whom received a prior antibiotic therapy that may have selected-out for the organism (139, 140). Moreover, Husni et al (141) reviewed the cases of 45 patients with clinically significant lactobacillemia and reported that 11 of the patients were receiving immunosup- pressive therapy and 23 had received antibiotics. In none of these reports was a definitive link made between the consumption of fermented milk products and infection. In addition, rare cases of endocarditis have been associated with L. rhamnosus, a LAB indigenous to the human gastrointes- tinal tract (142144). However, as with lactobacillemia, no re- ports to date have been able to identify a connection between LAB from fermented milk and infection in humans. In most of these cases, the origin of the Lactobacillus is most likely the host. There is also a hypothetical risk of the transfer of antimicrobial resistance from LAB to other microorganisms with which LAB might come in contact, but this has not yet been described in the literature. In the past, Lactobacilli isolated from infections were habit- ually dismissed as contaminants or secondary invaders. However, recent evidence suggests that they might function as opportunistic pathogens in a small number of severely immunosuppressed persons. Even in these patients, this is a very rare event, and it has not yet been reported in a large group of immunosuppressed persons, such as the elderly or persons with AIDS. LAB have a long history of safe use in foods and also in products that have been tested in clinical trials. However, as with any new food ingredient, the safety of a new strain of LAB must be clearly established before it is introduced into fermented dairy products. CONCLUDING REMARKS AND RECOMMENDATIONS FOR FUTURE STUDIES It has long been believed that the consumption of yogurt and other fermented milk products provides various health benefits. Recent studies of the possible health benefits of yogurt in gut- associated diseases substantiate some of these beliefs. Of partic- ular interest are the reductionby yogurt, yogurt bacteria, or bothin the duration of diarrheal diseases in children, the pre- ventive or therapeutic (or both) effects on IBD and colon cancer as suggested by epidemiologic evidence and animal studies, and the possible beneficial effects inincreasingthe eradicationrate of H. pylori as indicated by in vitro and preliminary human studies. In addition, there is ever-increasing evidence of the beneficial effect of yogurt containing live and active cultures on the diges- tion of lactose in persons with lactose intolerance. These findings are interesting and should encourage future studies to1) substantiate or extendthese findings byusinganimal models and clinical trials; 2) ascertain whether these effects are age-specific or can be observed across all age groups: eg, ascer- tain whether yogurt would have effects similar to those observed in children on attenuation of the incidence or duration of diar- rheal diseases in elderly people, a group that has high morbidity and mortality fromthese infections; and 3) investigate the mech- anisms through which yogurt exerts its effects and ascertain the critical components of yogurt involved in its mechanisms of action. Finally, in recent years, yogurt has been touted as im- proving gut health. In the absence of a universally accepted definition or any definition of gut health, it is difficult to sub- stantiate these claims. Studies focused on determining the char- acteristics of a healthy gut would be extremely helpful in eval- uating the effect of yogurt on gut health. All 3 authors participated in the literature review and the development of the manuscript outline, and SNM and RMR determined the areas to be discussed. OA conducted the literature search and organized and wrote the manuscript. SNM provided corrections. RMR revised the manuscript. This review was prepared in response to a request from the National Yogurt Association for a critical and objective review, for which the authors received an honorarium. REFERENCES 1. Guarner F, Schaafsma GJ. Probiotics. Int J Food Microbiol 1998;39: 2378. 2. Bourlioux P, Pochart P. Nutritional and health properties of yogurt. World Rev Nutr Diet 1988;56:21758. YOGURT AND GUT FUNCTION 253
b y
g u e s t
o n
M a r c h
2 ,
2 0 1 4 a j c n . n u t r i t i o n . o r g D o w n l o a d e d
f r o m
3. Chandan RC, Shahani KM. Yogurt. In: Hui YH, ed. Dairy science and technology handbook. New York: VCH Publishers, Inc, 1993:157. 4. Metchnikoff E. Sur la flore du corps humain. (On the flora of the human body. ) Manch Lit Philos Soc 1901;45:138 (in French). 5. Perdigon G, Alvarez S, Rachid M, Aguero G, Gobbato NJ. Immune system stimulation by probiotics. J Dairy Sci 1995;78:1597606. 6. Buttriss J. Nutritional properties of fermentedmilkproducts. Int J Dairy Tech 1997;50:217. 7. ReddyKP, Shahani KM, Kulkarni SM. B-complexvitamins incultured and acidified yogurt. J Dairy Sci 1976;59:1915. 8. Shahani KM, Chandan RC. Nutritional and healthful aspects of cul- turedandculture-containingdairyfoods. J DairySci 1979;62:168594. 9. Kneifel W, Mayer HK. Vitamin profiles of kefirs made from milks of different species. Int J Food Sci Technol 1991;26:4238. 10. Kneifel W, Kaufmann M, Fleischer A, Ulberth F. Screening of com- mercially available mesophilic dairy starter cultures: biochemical, sen- sory and morphological properties. J Dairy Sci 1992;75:315866. 11. Crittenden RG, Martinez NR, Playne MJ. Synthesis and utilisation of folate by yoghurt starter cultures and probiotic bacteria. Int J Food Microbiol 2003;80:21722. 12. Wigertz K, Svensson UK, Jagerstad M. Folate and folate binding pro- tein content in dairy products. J Dairy Res 1996;64:23954. 13. Rosado JL, Solomons NW, Allen LH. Lactose digestion from unmod- ified, low-fat and lactose-hydrolyzed yogurt in adult lactose maldigest- ers. Eur J Clin Nutr 1992;46:617. 14. Vesa TH, Marteau P, Korpela R. Lactose intolerance. J Am Coll Nutr 2000;19:165S75S. 15. Kolars JC, Levitt MD, Aouji M, Savaiano DA. Yogurtan autodigest- ing source of lactose. N Engl J Med 1984;310:13. 16. Goodenough ER, Kleyn DH. Influence of viable yogurt microflora on digestion of lactose by the rat. J Dairy Sci 1976;59:6016. 17. Rasic JL, Kurmann JA. Yoghurt: scientific grounds, technology, man- ufacture and preparations. Vol 1 of Rasic JL, Kurmann JA, eds. Fer- mented fresh milk products and their cultures. Copenhagen: Technical Dairy Publishing House, 1978. 18. Loones A. Transformation of milk components during yogurt fermen- tation. In: Chandan RC, ed. Yogurt: nutritional and health properties. McLean, VA: National Yogurt Association, 1989:95114. 19. Beshkova DM, Simova ED, Frengova GI, Simov ZI, Adilov EF. Pro- duction of amino acids by yogurt bacteria. Biotechnol Prog 1998;14: 9635. 20. Hewitt D, Bancroft HJ. Nutritional value of yogurt. J Dairy Res 1985; 52:197207. 21. Bissonnette DJ, Jeejeebhoy KN, eds. Meeting dietary nutrient require- ments with cows milk and milk products. Rotterdam: Balkema, 1994. 22. Gaudichon C, Roos N, Mah S, Sick H, Bouley C, Tom D. Gastric emptying regulates the kinetics of nitrogen absorption from 15 N- labeled milk and 15 N-labeled yogurt in miniature pigs. J Nutr 1994; 124:19707. 23. Gaudichon C, Mah S, Roos N, et al. Exogenous and endogenous nitrogen flow rates and level of protein hydrolysis in the human jeju- num after [ 15 N] milk and [ 15 N] yogurt ingestion. Br J Nutr 1995;74: 25160. 24. Shantha NC, Ram LN, OLeary J, Hicks CL, Decker EA. Conjugated linoleic acid concentrations in dairy products as affected by processing and storage. J Food Sci 1995;60:6958. 25. Aneja RP, Murthi TN. Conjugated linoleic acid contents of Indian curd and ghee. Indian J Dairy Sci 1990;43:2318. 26. Jiang J, Wolk A, Vessby B. Relation between the intake of milk fat and the occurrence of conjugated linoleic acid in human adipose tissue. Am J Clin Nutr 1999;70:217. 27. Park Y, McGuire MK, Behr R, McGuire MA, Evans MA, Schultz TD. High-fat dairy product consumption increases 9c; 11t18:2 (rumenic acid) and total lipid concentrations of human milk. Lipids 1999;34: 5439. 28. Boccignone M, Brigidi R, Sarra C. Studi effettuati sulla compo-sizione in trigliceridi ed acidi grassi liberi nello yogurt preparato dalatte vac- cino, pecorinoe, caprino. (Studies on triglyceride and free fatty acid composition of yogurt prepared from cow, goat, and sheep milk.) Ann Fac Med Vet (Torino) 1984;28:22333 (in Italian). 29. Whigham LD, Cook ME, Atkinson RL. Conjugated linoleic acid: im- plications for human health. Pharmacol Res 2000;42:50310. 30. KempMQ, JeffyBD, RomagnoloDF. Conjugatedlinoleic acidinhibits cell proliferation through a p53-dependent mechanism: effects on the expression of G1-restriction points in breast and colon cancer cells. J Nutr 2003;133:36707. 31. Block G, Abrams B. Vitamin and mineral status of women of child- bearing potential. Ann N Y Acad Sci 1993;678:24454. 32. Ervin RB, Kennedy-Stephenson J. Mineral intakes of elderly adult supplement and non-supplement users in the third National Health and Nutrition Examination Survey. J Nutr 2002;132:34227. 33. Allen LH. Calciumbioavailability and absorption: a review. AmJ Clin Nutr 1982;35:783808. 34. KaupSM, Shahani KM, Amer MA, PeoER. (Bioavailabilityof calcium in yogurt.) Milchwissenschaft 1987;42:5136 (in German). 35. Schaafsma GJ, Dekker PR, de Ward H. Nutritional aspects of yogurt. 2. Bioavailability of essential minerals and trace elements. Neth Milk Dairy J 1988;42:13546. 36. Bronner F, Pansu D. Nutritional aspects of calcium absorption. J Nutr 1999;129:912. 37. Norman AW. Intestinal calcium absorption: a vitamin D-hormone mediated adaptive response. Am J Clin Nutr 1990;51:290300. 38. Pointillart A, Cayron B, Gueguen L. Calcium and phosphorus utiliza- tion and bone mineralization in yogurt-fed pigs. Sci Alim 1986;6:15 30. 39. Bernet MF, Brassart D, Neeser JR, Servin AL. Lactobacillus acidophi- lus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut 1994;35: 4839. 40. Alm L, Pettersson L. Survival rate of lactobacilli during digestion: an in vitro study Am J Clin Nutr 1980;33(suppl):S2543 (abstr). 41. Robins-Browne RM, Path FF, Levine MM. The fate of ingested lacto- bacilli in the proximal small intestine. AmJ Clin Nutr 1981;34:5149. 42. Conway PL, Gorbach SL, Goldin BR. Survival of lactic acid bacteria in the human stomach and adhesion to intestinal cells. J Dairy Sci 1987; 70:112. 43. Pedrosa MC, Golner BB, Goldin BR, Barakat S, Dallal GE, Russell RM. Survival of yogurt-containing organisms and Lactobacillus gas- seri (ADH) and their effect on bacterial enzyme activity in the gastro- intestinal tract of healthy and hypochlorhydric elderly subjects. Am J Clin Nutr 1995;61:3539. 44. Clark PA, Martin JH. Selection of bifidobacteria for use as dietary adjuvants in cultured dairy foods: III. Tolerance to stimulated bile concentrations of human small intestines. Cult Dairy Prod J 1994;29: 1821. 45. Duez H, Pelletier H, Cools S, et al. A colony immunoblotting method for quantitative detectionof a Bifidobacteriumanimalis probiotic strain in human faeces. J Appl Microbiol 2000;88:101927. 46. Guerin-Danan C, Chabanet C, Pedone C, et al. Milk fermented with yogurt cultures and Lactobacillus casei compared with yogurt and gelled milk: influence on intestinal microflora in healthy infants. Am J Clin Nutr 1998;67:1117. 47. Bouhnik Y, Pochart P, Marteau P, Arlet G, Goderel I, Rambaud JC. Fecal recovery in humans of viable Bifidobacterium sp ingested in fermented milk. Gastroenterology 1992;102:8758. 48. Plant L, Conway P. Association of Lactobacillus spp. with Peyers patches in mice. Clin Diagn Lab Immunol 2001;8:3204. 49. Bernet MF, Brassart D, Neeser JR, Servin AL. Adhesion of human bifidobacterial strains to cultured human intestinal epithelial cells and inhibition of enteropathogen-cell interactions. Appl Env Microbiol 1993;59:41218. 50. Lerebours E, N'Djitoyap NdamC, Lavoine A, Hellot MF, Antoine JM, Colin R. Yogurt and fermented-then-pasteurized milk: effects of short- termand long-termingestion on lactose absorption and mucosal lactase activity in lactase-deficient subjects. Am J Clin Nutr 1989;49:8237. 51. Kankaanpaa P, Salminen SJ, Isolauri E, Lee YK. The influence of polyunsaturated fatty acids on probiotic growth and adhesion. FEMS Microbiol Lett 2001;194:14953. 52. Kankaanpaa P, Yang B, Kallio H, Isolauri E, Salminen S. Effects of polyunsaturated fatty acids in growth mediumon lipid composition and on physicochemical surface properties of Lactobacilli. Appl Env Mi- crobiol 2004;70:12936. 53. Aguirre M, Collins MD. Lactic acid bacteria and human clinical infec- tion. J Appl Bacteriol 1993;75:95107. 54. Brandtzaeg P, Baekkevold ES, Farstad IN, et al. Regional specializa- tion in the mucosal immune system: what happens in the microcom- partments? Immunol Today 1999;20:14151. 55. Macpherson AJ, Gatto D, Sainsbury E, Harriman GR, Hengartner H, 254 ADOLFSSON ET AL
b y
g u e s t
o n
M a r c h
2 ,
2 0 1 4 a j c n . n u t r i t i o n . o r g D o w n l o a d e d
f r o m
Zinkernagel RM. A primitive T cell-independent mechanism of intes- tinal mucosal IgAresponses to commensal bacteria. Science 2000;288: 22226. 56. Puri P, Rattan A, Bijlani RL, Mahapatra SC, Nath I. Splenic and intes- tinal lymphocyte proliferation response in mice fed milk or yogurt and challenged with Salmonella typhimurium. Int J Food Sci Nutr 1996; 47:3918. 57. Link-Amster H, Rochat F, Saudan KY, Mignot O, Aeschlimann JM. Modulation of a specific humoral immune response and changes in intestinal flora mediated through fermented milk intakes. FEMS Im- munol Med Microbiol 1994;10:5564. 58. Perdigon G, de Macias ME, Alvarez S, Oliver G, de Ruiz Holgado AA. Systemic augmentation of the immune response in mice by feeding fermented milks with Lactobacillus casei and Lactobacillus acidophi- lus. Immunology 1988;63:1723. 59. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:234857. 60. Miettinen M, Vuopio-Varkila J, Varkila K. Production of human tumor necrosis factor-alpha, interleukin-6 and interleukin-10 is induced by lactic acid bacteria. Infect Immun 1996;64:54035. 61. Solis-Pereyra B, Aattouri N, Lemonnier D. Role of food in the stim- ulation of cytokine production. Am J Clin Nutr 1997;66(suppl): 521S5S. 62. Halpern GM, Vruwink KG, van de Water J, Keen CL, Gershwin ME. Influence of long-term yogurt consumption in young adults. Int J Im- munother 1991;7:20510. 63. Borruel N, Carol M, Casellas F, et al. Increased mucosal tumour ne- crosis factor alpha production in Crohns disease can be downregulated ex vivo by probiotic bacteria. Gut 2002;51:65964. 64. De Simone C, Bianchi Salvadori B, Negri M, Ferrazzi M, Baldinelli L, Vesely R. The adjuvant effect of yogurt on production of gamma- interferon by Con A stimulated human peripheral blood lymphocytes. Nutr Rep Int 1986;33:41933. 65. Beharka AA, Paiva S, Leka LS, Ribaya-Mercado JD, Russell RM, Nibkin Meydani S. Effect of age on the gastrointestinal-associated mucosal immune response of humans. J Gerontol A Biol Sci Med Sci 2001;56:B21823. 66. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347: 41729. 67. Ajuebor MN, SwainMG. Role of chemokines andchemokine receptors in the gastrointestinal tract. Immunology 2002;105:13743. 68. Wallace TD, Bradley S, Buckley ND, Green-Johnson JM. Interactions of lactic acid bacteria with human intestinal epithelial cells: effects on cytokine production. Food Prot 2003;66:46672. 69. Strandhagen E, Lia A, Lindstrand S, et al. Fermented milk (ropy milk) replacing regular milk reduces glycemic responce and gastric emptying in healthy subjects. Scand J Nutr 1994;38:11721. 70. Nakamura T, Nishida S, Mizutani M, Iino H. Effects of yogurt supple- mented with brewers yeast cell wall on constipation and intestinal microflora in rats. J Nutr Sci Vitaminol (Tokyo) 2001;47:36772. 71. Meance S, Cayuela C, Turchet P, Raimondi A, Lucas C, Antoine JM. A fermented milk with a Bifidobacterium probiotic strain DN-173 010 shortened oro-fecal gut transit time in elderly. Microb Ecol Health Dis 2001;13:21722. 72. Marteau P, Cuillerier E, Meance S, et al. Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. Aliment Pharmacol Ther 2002;16:58793. 73. Rorick MH, Scrimshaw NS. Comparative tolerance of elderly from differing ethnic backgrounds to lactose-containing and lactose-free dairy drinks: a double-blind study. J Gerontol 1979;34:1916. 74. Sahi T. Genetics and epidemiology of adult-type hypolactasia. Scand J Gastroenterol 1994;202:720. 75. Savaiano DA, AbouElAnouar A, Smith DE, Levitt MD. Lactose mal- absorption from yogurt, pasteurized yogurt, sweet acidophilus milk, and cultured milk in lactase-deficient individuals. Am J Clin Nutr 1984;40:121923. 76. Pochart P, Dewit O, Desjeux JF, Bourlioux P. Viable starter culture, -galactosidase activity, and lactose in duodenum after yogurt inges- tion in lactase-deficient humans. Am J Clin Nutr 1989;49:82831. 77. HickeyMW, Hillier AJ, JagoGR. Transport andmetabolismof lactose, glucose, and galactose in homofermentative lactobacilli. Appl Environ Microbiol 1986;51:82531. 78. Foucaud C, Poolman B. Lactose transport system of Streptococcus thermophilus. J Biol Chem 1992;267:2208794. 79. Thoreux K, Balas D, Bouley C, Senegas-Balas F. Diet supplemented with yoghurt or milk fermented by Lactobacillus casei DN-114 001 stimulates growth and brush-border enzyme activities in mouse small intestine. Digestion 1998;59:34959. 80. Martini MC, Bollweg GL, Levitt MD, Savaiano DA. Lactose digestion by yogurt -galactosidase: influence of pHand microbial cell integrity. Am J Clin Nutr 1987;45:4326. 81. Glass RI, Lew JF, Gangarosa RE, LeBaron CW, Ho MS. Estimates of morbidity and mortality rates for diarrheal diseases in American chil- dren. J Pediatr 1991;118:S2733. 82. VanNeil CW, Feudtner C, GarrisonMM, Christakis DA. Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. Pe- diatrics 2002;109:67884. 83. Saavedra JM, Bauman NA, Oung I, Perman JA, Yolken RH. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in a hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 1994;344:10469. 84. Gorbach SL, Chang TW, Goldin B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet 1987;2: 1519(letter). 85. Biller JA, Katz AJ, Flores AF, Buie TM, Gorbach SL. Treatment of recurrent Clostridium difficile colitis with Lactobacillus GG. J Pediatr Gastroenterol Nutr 1995;21:2246. 86. Shornikova AV, Isolauri E, Burkanova L, Lukovnikova S, Vesikari T. A trial in the Karelian Republic of oral rehydration and Lactobacillus GG for treatment of acute diarrhoea. Acta Paediatr 1997;86:4605. 87. Clements ML, Levine MM, Ristaino PA, Daya VE, Huges TP. Exog- enous lactobacilli fed to mantheir fate and ability to prevent diarrheal disease. Prog Food Nutr Sci 1983;7:2937. 88. Bartlett JG. Antibiotic-associated diarrhea. Clin Infect Dis 1992;15: 57381. 89. Van der Waaij D. The ecology of the human intestine and its conse- quences for overgrowth by pathogens such as Clostridium difficile. Annu Rev Microbiol 1989;43:6987. 90. DSouza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics inprevention of antibiotic associated diarrhoea: meta-analysis. BMJ 2002;324:16. 91. Gotz V, Romankiewicz JA, Moss J, Murray HW. Prophylaxis against ampicillin associated diarrhoea with Lactobacillus preparation. Am J Hosp Pharm 1979;36:7547. 92. Tankanow RM, Ross MB, Ertel IJ, Dickinson DG, McCormick LS, Garfinkel JF. A double blind, placebo-controlled study of the efficacy of Lactinex in the prophylaxis of amoxicillin-induced diarrhea. DICP 1990;24:3824. 93. Orrhage K, Brismar B, Nord CE. Effects of supplements of Bifidobac- terium longum and Lactobacillus acidophilus on intestinal microbiota during administration of clindamycin. Microb Ecol Health Dis 1994; 7:1725. 94. Vanderhoof JA, Whitney DB, Antonson DL, Hanner TL, Lupo JV, Young RJ. Lactobacillus GGin the prevention of antibiotic-associated diarrhoea in children. J Pediatr 1999;135:35668. 95. National Cancer Institute. SEER Cancer Incidence Public-Use Data- base, 1973-1996, August 1998 Submission. Bethesda, MD: US De- partment of Health and Human Services, Public Health Service, 1999. 96. Peters RK, Pike MC, Garabrant D, Mack TM. Diet and colon cancer in Los Angeles County, California. Cancer Causes Control 1992;3: 45773. 97. ReddyBS, RivensonA. Inhibitoryeffect of Bifidobacteriumlongumon colon, mammary, and liver carcinogenesis induced by 2-amino-3- methylimidazo[4,5-f]quinoline, a food mutagen. Cancer Res 1993;53: 39148. 98. Ayebo AD, Shahani KM, Dam R. Antitumor component(s) of yogurt: fractionation. J Dairy Sci 1981;64:231823. 99. Shackelford LA, Rao DR, Chawan CB, Pulusani SR. Effect of feeding fermented milk on the incidence of chemically induced colon tumors in rats. Nutr Cancer 1983;5:15964. 100. Wollowski I, Ji S, Bakalinsky AT, Neudecker C, Pool-Zobel BL. Bac- teria used for the production of yogurt inactivate carcinogens and pre- vent DNA damage in the colon of rats. J Nutr 1999;129:7782. 101. Bolognani F, Rumney CJ, Pool-Zobel BL, Rowland IR. Effect of YOGURT AND GUT FUNCTION 255
b y
g u e s t
o n
M a r c h
2 ,
2 0 1 4 a j c n . n u t r i t i o n . o r g D o w n l o a d e d
f r o m
lactobacilli, bifidobacteria and inulin on the formation of aberrant crypt foci in rats. Eur J Nutr 2001;40:293300. 102. Ganjam LS, Thornton WH, Marshall RT, MacDonald RS. Antiprolif- erative effects of yogurt fractions obtained by membrane dialysis on cultured mammalian intestinal cells. J Dairy Sci 1997;80:23259. 103. Kim DH, Jin YH. Intestinal bacterial beta-glucuronidase activity of patients with colon cancer. Arch Pharm Res 2001;24:5647. 104. Reddy BS, Engle A, Simi B, Goldman M. Effect of dietary fiber on colonic bacterial enzymes and bile acids in relation to colon cancer. Gastroenterology 1992;102:147582. 105. GoldinBR, GorbachSL. Alterations of the intestinal microflora bydiet, oral antibiotics, andLactobacillus: decreasedproductionof free amines from aromatic nitro compounds, azo dyes, and glucuronides. J Natl Cancer Inst 1984;73:68995. 106. GoldinBR, GorbachSL. The effect of milkandlactobacillus feedingon human intestinal bacterial enzyme activity. Am J Clin Nutr 1984;39: 75661. 107. Rafter JJ. The role of lactic acid bacteria in colon cancer prevention. Scand J Gastroenterol 1995;30:497502. 108. Sartor RB. Pathogenesis and immune mechanisms of chronic inflam- matory bowel diseases. Am J Gastroenterol 1997;92:5S11S. 109. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003;138:80711. 110. Fabia R, ArRajabA, JohanssonML, et al. Impairment of bacterial flora in human ulcerative colitis and experimental colitis in the rat. Digestion 1993;54:24855. 111. McCormick DA, Horton LW, Mee AS. Mucin depletion in inflamma- tory bowel disease. J Clin Pathol 1990;43:1436. 112. van Wijngaarden P, Meijssen MA. Tuberculous pleurisy: an unusual complication during treatment of Crohn disease with azathioprine. Scand J Gastroenterol 2001;37:10047. 113. Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN. Lac- tobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999;116:110714. 114. Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000;289:13525. 115. Malin M, Suomalainen H, Saxelin M, Isolauri E. Promotion of IgA immune response in patients with Crohns disease by oral bacterio- therapy with Lactobacillus GG. Ann Nutr Metab 1996;40:13745. 116. Kaila M, Isolauri E, Soppi E, Virtanen E, Laine S, Arvilommi H. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain. Pediatr Res 1992;32: 1414. 117. Marshall BJ. Unidentified curved bacillus on gastric epithelium in active chronic gastritis. Lancet 1983;1:12735. 118. Labigne A, de Reuse H. Determinants of Helicobacter pylori patho- genicity. Infect Agents Dis 1996;5:191202. 119. Duggan A. Helicobacter pylori: when is treatment now indicated? Int Med J 2002;32:4659. 120. Aiba Y, Suzuki N, Kabir AMA, Takagi A, Koga Y. Lactic acid- mediated supression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnobiotic murine model. Am J Gastroenterol 1998;93:2097101. 121. MidoloPD, Lambert JR, Hull R, LuoF, GraysonML. Invitroinhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. J Appl Bacteriol 1995;79:4759. 122. Coconnier M, Lievin V, Hemery E, Servin AL. Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB. Appl Env Microbiol 1998;64: 457380. 123. KimTS, Hur JW, Yu MA, et al. Antagonismof Helicobacter pylori by bacteriocins of lactic acid bacteria. J Food Prot 2003;66:312. 124. Armuzzi A, Cremonini F, Ojetti V, et al. Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study. Digestion 2001;63:17. 125. Michetti P, Dorta G, Wiesel PH, et al. Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helico- bacter pylori infection in humans. Digestion 1999;60:2039. 126. Sakamoto I, Igarashi M, Kimura K, Takagi A, Miwa T, Koga Y. Sup- pressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helico- bacter pylori infection in humns. J Antimicrob Chemother 2001;47: 70910. 127. Cats A, Kuipers EJ, Bosschaert MAR, Pot RGJ, Vandenbroucke- Grauls CMJE, Kusters JG. Effect of frequent consumption of a Lacto- bacillus casei-containing milk drink in Helicobacter pylori-colonized subjects. Aliment Pharmacol Ther 2003;17:42935. 128. Kalliomaki M, Isolauri E. Role of intestinal flora in the development of allergy. Curr Opin Allergy Clin Immunol 2003;3:1520. 129. Kirjavainen PV, Salminen SJ, Isolauri E. Probiotic bacteria in the management of atopic disease: underscoring the importance of viabil- ity. J Pediatr Gastroenterol Nutr 2003;36:2237. 130. Isolauri E. Studies on Lactobacillus GG in food hypersensitivity dis- orders. Nutr Today 1996;31:28S31S. 131. Gurr MI. The nutritional role of cultured dairy products. Can Inst Food Sci Technol 1984;17:5764. 132. Rytknen J, Karttunen TJ, Karttunen R, et al. Effect of heat denatur- ation on beta-lactoglobulin-induced gastrointestinal sensitization in rats: denatured LG induces a more intensive local immunologic re- sponse than native LG. Pediatr Allergy Immunol 2002;13:26977. 133. Bischoff SC, Mayer JH, Manns MP. Allergy and the gut. Int Arch Allergy Immunol 2000;121:27083. 134. Miettinen M, Matikainen S, Vuopio-Varkila J, et al. Lactobacilli and streptococci induce interleukin-12 (IL-12), IL-18, and gamma inter- feron production in human peripheral blood mononuclear cells. Infect Immun 1998;66:605862. 135. Shida K, Makino K, Morishita A, et al. Lactobacillus casei inhibits antigen-induced IgE secretion through regulation of cytokine produc- tion in murine splenocyte cultures. Int Arch Allergy Immunol 1998; 115:27887. 136. Gasser F. Safety of lactic acid bacteria and their occurrence in human clinical infection. Bull Inst Pasteur 1994;92:4567. 137. MacGregor G, Smith AJ, Thakker B, Kinsella J. Yoghurt biotherapy: contraindicated in immunosuppressed patients? Postgrad Med J 2002; 78:3667. 138. Schlegel L, Lemerle S, Geslin P. Lactobacillus species as opportunistic pathogens in immune-compromised patients. Eur J Clin Microbiol Infect Dis 1998;17:8878. 139. Bayer AS, Chow AW, Betts D, Guze LB. Lactobacillemiareport of nine cases. Important clinical and therapeutic considerations. Am J Med 1978;64:80813. 140. Horwitch CA, Furseth HA, Larson AM, Jones TL, Olliffe JF, Spach DH. Lactobacillemia in three patients with AIDS. Clin Infect Dis 1995; 21:14602. 141. Husni RN, Gordon SM, Washington JA, Longworth DL. Lactobacillus bacteremia and endocarditis: review of 45 cases. Clin Infect Dis 1997; 25:104855. 142. Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JMT. Lacto- bacillus endocarditis caused by a probiotic organism. Clin Microbiol Infect 1999;5:2902. 143. Presterl E, Kneifel W, Mayer HK, Zehetgruber M, Makristathis A, Graninger W. Endocarditis by Lactobacillus rhamnosus due to yogurt ingestion? Scand J Infect Dis 2001;33:7104. 144. Avlami A, Kordossis T, Vrizidis N, Sipsas NV. Lactobacillus rham- nosus endocarditis complicating colonoscopy. J Infect 2001;42:2835. 256 ADOLFSSON ET AL
b y
g u e s t
o n
M a r c h
2 ,
2 0 1 4 a j c n . n u t r i t i o n . o r g D o w n l o a d e d